IGC Pharma, Inc.

IGC NYSE SEC CIK 1326205
Follow IGC Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · US GAAP
Revenue, last quarter $422K
Net income −$2.5M
EPS, diluted -
Operating cash flow −$568K

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$1.3M−$7.1M
FY24$1.3M−$13M
FY23$911K−$11.5M
FY22$397K−$15M
FY21$898K−$8.8M
FY20$4.1M−$7.3M
FY19$5.1M−$4.1M
FY18$2.2M−$1.8M
FY17$580.4K−$1.9M
FY16$6.4M−$2.8M
FY15$7.7M−$4.6M
FY14$2.3M−$3M
FY13$8M−$2.3M
FY12$4.2M−$7.8M
FY11$4.1M−$20.2M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%1000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2548.7%−585.8%−560.3%
FY2454.5%−728.5%−966.5%
FY2348.5%−1270.1%−1263%
FY2248.9%−3886.1%−3782.4%
FY2112.6%−971.5%−981.2%
FY202.8%−168.6%−179.6%
FY192.6%−90.8%−80.1%
FY183.7%−81.6%−81.4%
FY1737.6%−354%−321.7%
FY1613.2%−45.6%−44.1%
FY157.5%−56.5%−60.1%
FY1416.8%−111.2%−133%
FY1319.1%−30.9%−28%
FY12−14.7%−178.9%−184.6%
FY113.9%−390%−496.8%
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0$5MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$4.9M
FY24−$5.3M
FY23−$7.4M
FY22−$7.7M
FY21−$12.3M
FY20−$13.1M
FY19−$3.3M
FY18−$2.1M
FY17−$1.5M
FY16−$279.9K
FY15−$2.7M
FY14−$1.8M
FY13$238.8K
FY12−$5M
FY11−$2.9M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • IGC Pharma
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearIGC PharmaHealthcare median
FY25−560.3%−30.6%
FY24−966.5%−47%
FY23−1263%−58%
FY22−3782.4%−80.4%
FY21−981.2%−71.9%
FY20−179.6%−62.2%
FY19−80.1%−46.3%
FY18−81.4%−49.6%
FY17−321.7%−45.9%
FY16−44.1%−36%
FY15−60.1%−38.4%
FY14−133%−35.5%
FY13−28%−37.1%
FY12−184.6%−29.1%
FY11−496.8%−27.9%